|  |  |
| --- | --- |
|  | **NHS Prescription Services**  Bridge House  152 Pilgrim Street  Newcastle upon Tyne  NE1 6SN  0845 850 0001  Email:[nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)  Website:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  20 Jan 2025 |
|  |

VERSION 1.3.0

Dear dm+d User,

**SNOMED International Proposal to Increase Description Length Limit**

We are providing an update to the [information previously communicated](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the proposal from SNOMED International to increase the maximum length of Fully Specified Name and Synonym descriptions,.

SNOMED International have provided [further information](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1154361&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) about the [proposal to increase description length limit](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) from 255 to 4096 characters.

NHS England are currently assessing whether this proposed change will impact Fully Specified Names (FSN) created in the SNOMED CT UK Drug Extension. NHS England do not expect that this proposed change will impact Preferred Terms (PT) in the SNOMED CT UK Drug Extension.

This proposal will impact UK users of the **Medicinal Product Hierarchy of the SNOMED International Edition** (both SNOMED CT International Edition and SNOMED CT UK Edition release packages) but dm+d will NOT be affected and we have no plans to adopt these changes.

The planned implementation date for **SNOMED International** **changes is January 2026** and will come into effect in the **April 2026 UK release**.

Any concerns or queries should be directed to SNOMED International at [release@snomed.org](mailto:release@snomed.org). Please cc [information.standards@nhs.net](mailto:information.standards@nhs.net) to enable NHS England to have visibility of UK stakeholder feedback.

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

We are providing an update to information posted in [September](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1113177&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension.

The VTM Ingredient XML file will be maintained from Monday 18 November and the VTM Ingredients that need populating will be gradually added over a period of time.  We will provide confirmation when this has been completed.

The weekly dm+d extract will be added to TRUD and the NHS Terminology Server as usual and will include the live VTM Ingredients XML file.

**Please note that VTM Ingredients information will only be available via TRUD and the NHS England Terminology Server from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.**

Additional information about the change is available on the following [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ukmeds@nhs.net)

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact [medicinestandards@nhs.net](mailto:medicinestandards@nhs.net) for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** | | | |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Hydrogen peroxide 3% solution | 42510811000001109 | Imported | 18/12/2023 |
| Cerium nitrate hexahydrate 22mg/g / Sulfadiazine silver 10mg/g cream | 42991011000001101 | Imported | 01/07/2024 |
| Sulfadiazine silver 1% cream | 42990711000001107 | Imported | 01/07/2024 |
| Creon 10000 capsules | 43034611000001101 | Imported | 15/07/2024 |
| Creon 25000 capsules | 43034811000001102 | Imported | 15/07/2024 |
| Pancreaze Delayed-Release capsules | 43035111000001108 | Imported | 15/07/2024 |
| Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 43093511000001105 | Imported | 22/07/2024 |
| Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 43094411000001109 | Imported | 22/07/2024 |
| Methylphenidate 18mg modified-release tablets | 43210911000001100 | Imported | 02/09/2024 |
| Methylphenidate 27mg modified-release tablets | 43211511000001100 | Imported | 02/09/2024 |
| Methylphenidate 36mg modified-release tablets | 43211911000001107 | Imported | 02/09/2024 |
| Methylphenidate 54mg modified-release tablets | 43212411000001109 | Imported | 02/09/2024 |
| Pangrol 10,000 capsules | 43788211000001100 | Imported | 23/09/2024 |
| Pangrol 25,000 capsules | 43788511000001102 | Imported | 23/09/2024 |
| Imiquimod 5% cream 250mg sachets | 41526711000001106 | Imported | 02/12/2024 |

**Invalidation****s**

The following concept has been invalidated as it was outdated.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**  Ammonia solution strong 8.698g / Eucalyptus oil 500mg granules | **VMP**  Generic Mackenzies Smelling Salts |
| **VMP SNOMED ID**  10050811000001105 | **VMP SNOMED ID**  44078611000001106 |
| **VMPP**  17 ml | **VMPP**  17 ml |
| **VMPP SNOMED ID**  10038611000001105 | **VMPP SNOMED ID**  44076811000001109 |
| **AMP**  Mackenzies Smelling Salts (Dexcel-Pharma Ltd) | **AMP**  Mackenzies Smelling Salts (Dexcel-Pharma Ltd) |
| **AMP SNOMED ID**  10038811000001109 | **AMP SNOMED ID**  44076911000001104 |
| **AMPP**  17 ml | **AMPP**  17 ml |
| **AMPP SNOMED ID**  10038911000001104 | **AMPP SNOMED ID**  44077111000001104 |

The following concept has been invalidated as it was outdated

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**  Paclitaxel albumin 100mg powder for suspension for infusion vials | **VMP**  Paclitaxel albumin 100mg powder for dispersion for infusion vials |
| **VMP SNOMED ID**  20177211000001100 | **VMP SNOMED ID**  39363111000001102 |
| **VMPP**  1 vial | **VMPP**  1 vial |
| **VMPP SNOMED ID**  20158811000001103 | **VMPP SNOMED ID**  39339711000001105 |
| **AMP**  Abraxane 100mg powder for suspension for infusion vials (Bristol-Myers Squibb Pharmaceuticals Ltd) | **AMP**  Abraxane 100mg powder for dispersion for infusion vials (Bristol-Myers Squibb Pharmaceuticals Ltd) |
| **AMP SNOMED ID**  20158911000001108 | **AMP SNOMED ID**  44137811000001101 |
| **AMPP**  1 vial | **AMPP**  1 vial |
| **AMPP SNOMED ID**  20159011000001104 | **AMPP SNOMED ID**  44138211000001103 |

The following concepts have been invalidated as they were added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Co-codamol 8mg/500mg effervescent tablets (VMP not to be made invalid) | **VMP** Co-codamol 8mg/500mg effervescent tablets sugar free |
| **VMP SNOMED ID** 42010111000001100(Not to be made invalid) | **VMP SNOMED ID** 38555211000001104 |
| **VMPP** 32(VMPP not to be made invalid) | **VMPP** 32 |
| **VMPP SNOMED ID** 10517511000001103 (Not to be made invalid) | **VMPP SNOMED ID** 40248711000001105 |
| **AMP** Co-codamol 8mg/500mg effervescent tablets (Cipla EU Ltd) | **AMP** Co-codamol 8mg/500mg effervescent tablets sugar free(Cipla EU Ltd) |
| **AMP SNOMED ID**  41143311000001109 | **AMP SNOMED ID** 44153911000001103 |
| **AMPP** 32 | **AMPP** 32 |
| **AMPP SNOMED ID** 41143811000001100 | **AMPP SNOMED ID** 44154011000001100 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Co-codamol 30mg/500mg effervescent tablets (VMP not to be made invalid) | **VMP** Co-codamol 30mg/500mg effervescent tablets sugar free |
| **VMP SNOMED ID** 42009711000001109 (Not to be made invalid) | **VMP SNOMED ID** 44159611000001106 |
| **VMPP** 100 (VMPP not to be made invalid) | **VMPP** 100 |
| **VMPP SNOMED ID** 1020711000001105 (Not to be made invalid) | **VMPP SNOMED ID** 44153511000001105 |
| **AMP** Co-codamol 30mg/500mg effervescent tablets (Cipla EU Ltd) | **AMP** Co-codamol 30mg/500mg effervescent tablets sugar free (Cipla EU Ltd) |
| **AMP SNOMED ID** 41145311000001105 | **AMP SNOMED ID** 44153711000001100 |
| **AMPP** 100 | **AMPP** 100 |
| **AMPP SNOMED ID** 41145411000001103 | **AMPP SNOMED ID** 44153811000001108 |

**Advance Notice of Invalidations**

The following concept will be invalidated mid-February as it was added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Daunorubicin 44mg / Cytarabine 100mg powder for solution for infusion vials | **VMP** Daunorubicin liposomal 44mg / Cytarabine liposomal 100mg powder for solution for infusion vials |
| **VMP SNOMED ID** 35812911000001103 | **VMP SNOMED ID** 44196811000001108 |
| **VMPP** 1 vial | **VMPP** 1 vial |
| **VMPP SNOMED ID** 35778211000001100 | **VMPP SNOMED ID** 44195211000001101 |
| **AMP** Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials (Jazz Pharmaceuticals UK Ltd) | **AMP** Vyxeos liposomal 44mg/100mg powder for concentrate for solution for infusion vials (Jazz Pharmaceuticals UK Ltd) |
| **AMP SNOMED ID**  35778311000001108 | **AMP SNOMED ID** 44195311000001109 |
| **AMPP** 1 vial | **AMPP** 1 vial |
| **AMPP SNOMED ID** 35778411000001101 | **AMPP SNOMED ID** 44195411000001102 |

The following concept will be invalidated mid-March as it was added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Amikacin 500mg/2ml solution for injection vials (not to be made invalid) | **VMP** Amikacin 500mg/2ml solution for injection ampoules |
| **VMP SNOMED ID** 35899911000001109 | **VMP SNOMED ID**  44422511000001103 |
| **VMPP** 5 vials (not to be made invalid) | **VMPP** 5 ampoule |
| **VMPP SNOMED ID** 4500011000001105 | **VMPP SNOMED ID** 44374911000001108 |
| **AMP** Amikacin 500mg/2ml solution for injection vials (Kent Pharma (UK) Ltd) | **AMP** Amikacin 500mg/2ml solution for injection ampoules (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID** 42788511000001107 | **AMP SNOMED ID** 44375011000001108 |
| **AMPP** 5 vials | **AMPP** 5 ampoule |
| **AMPP SNOMED ID** 42788611000001106 | **AMPP SNOMED ID** 44375111000001109 |

dm+d Authoring Team